1 Supplementary Informations

2

3 Methods

4 Study subjects

5 We enrolled 42 patients positive for SARS-CoV-2 who were admitted to the 6 Jikei University Hospital between March and May 2020 (approved by the Institutional 7 Review Board at The Jikei University School of Medicine (Number: 32-055(10130)). 8 COVID-19 patients were recruited on the basis of positive PCR tests for SARS-CoV-2 9 RNA obtained by nasopharyngeal swabs. The eventual degree of COVID-19 severity was 10 categorized as mild or severe on the basis of WHO 2020 scoring (Table S2). 11 Patients 11 with severe COVID-19 at admission were excluded. At the time of admission, all 12 COVID-19 patients were scored as having a mild status (WHO score = 3). Based on the 13 clinical disease course after admission, we divided 31 patients in two groups (namely, 14 Group 1: mild cases (WHO score ≤ 4), and Group 2: severe cases (WHO score ≥ 5)). All 15 patients received standard therapy without corticosteroids according to Clinical 16 management of COVID-19 interim guidance by WHO. 10 healthy age-matched donors were recruited at Omiya City Clinic, Saitama for routine medical examination between 17 18 March and April 2019 (approved by the Institutional Review Board at The Institute of 19 Medical Science, The University of Tokyo (Number: 28-19-0907). The medical records 20 of COVID-19 patients and healthy donors were analyzed retrospectively. 31 serum 21 samples taken at admission from COVID-19 patients and 10 serum samples taken from 22 healthy donors were separated by centrifugation at 3000 rpm for 10 min at 4°C. The 23 supernatant was collected into a new tube and the serum sample was stored at -80°C until 24 use.

25

26 Isolation of EVs

Anti-CD9 antibody and anti-CD63 antibody (H.U. Group Research Institute, Tokyo)
coupled to Dynabeads M-280 Tosylactivated (Thermo Fisher Scientific Inc, Waltham,
MA, USA) were added to aliquots (500 µL) of the serum samples that had been treated
with chelate-based PEVIA[®] reagent (H.U. Group Research Institute), followed by
incubation on a rotator at 4°C for 18 h. The beads were washed three times with PBS and
stored at 4°C until further analysis.

33

34 Preparation of peptides

35 EVs were processed using S-Trap micro spin columns (AMR Inc, Tokyo, Japan) 36 according to the manufacturer's instruction with minor modifications. In brief, captured 37 EVs were suspended in 50 µL of 5% SDS (FUJIFILM Wako Pure Chemical Corporation, 38 Osaka, Japan) in 50mM TEAB buffer (Honeywell Inc, Charlotte, NC, USA), pH7.5. After 39 removing beads, the amount of protein from EVs were determined by Micro BCA[™] Protein Assay Kit (Thermo Fisher Scientific Inc). 13.8 ng Pierce[™] Digestion Indicator 40 41 for Mass Spectrometry (Thermo Fisher Scientific Inc) was added to lysed samples for 42 quality control of digestion efficiency. The samples were then reduced and alkylated with 43 dithiothreitol (FUJIFILM Wako Pure Chemical Corporation) and iodoacetamide (Nacalai 44 tesque Inc, Kyoto, Japan), respectively. 12% aqueous phosphoric acid (FUJIFILM Wako 45 Pure Chemical Corporation) was added to a final concentration of 1.2% followed by six 46 times the volume of S-Trap protein binding buffer. The sample mixtures were added to 47 S-Trap columns that were prewashed and preconditioned with 0.2 % formic acid in 50 % 48 acetonitrile and S-Trap buffer, respectively. The S-Trap columns were washed with 49 150uL S-Trap buffer. Centrifugation and removal of the flow through were then repeated 50 6 times. Washed columns were incubated with 20uL of digestion buffer containing 0.75ug 51 Trypsin/Lys-C Mix, Mass Spec Grade (Promega Corporation, Madison, WI, USA) for 52 2hr at 47°C. After digestion, peptides were eluted from the S-Trap column, lyophilized 53 with miVac system (Genevac Ltd, Ipswich, United Kingdom), and stored at -80 °C until 54 use.

55

56 Proteomic analysis with LC-MS

57 Peptides obtained from EV proteins were reconstituted in 10 μ l of water containing 0.1% 58 formic acid (FA) (Fisher Chemical, Thermo Fisher Scientific Inc). Quantification of 59 peptides was accomplished using Pierce[™] Quantitative Fluorometric Peptide Assay 60 (Thermo Fisher Scientific Inc). Proteomic analysis of the peptides was carried out using 61 Q Exactive (Thermo Fisher Scientific Inc.) equipped with UltiMate 3000 Nano LC 62 Systems (Thermo Fisher Scientific Inc.). Peptide samples (1 µg) were injected onto 63 Acclaim PepMap 1000 trap columns (75 µm × 2 cm, nanoViper C18 3 µm, 100Å, Thermo 64 Fisher Scientific Inc) which were heated to 40 °C in a chamber which was connected to a C18 reverse-phase Aurora UHPLC Emitter Column with nano Zero & Captive Spray 65 66 Insert (75 μ m × 25 cm, Ion Opticks Pty Ltd) using Dreamspray interface (AMR Inc). The 67 nano pump flow rate was set to 250 nL/min with a 302 min gradient, in which the mobile phases were A (0.1% FA in water, Fisher Chemical, Thermo Fisher Scientific Inc.) and 68

B (0.1% FA in acetonitrile, Fisher Chemical, Thermo Fisher Scientific Inc.). The
chromatography gradient was designed to provide a linear increase from 0-8 min at 2%
B, 8-272 min from 2% B to 35% B, 272-282 min from 35% B to 70% B, 282-283 min
from 70% B to 95% B, wash, 8 min and 10 min equilibrium. The data-dependent
acquisition was performed in positive ion mode. Mass spectrometry parameters and those
of the Proteome Discoverer 2.2.0.388 software (Thermo Fisher Scientific Inc) were
described in a previous report (doi: https://doi.org/10.1101/2020.06.17.155861).

76

77 Analysis of serum exRNA profiles

78 Total RNA was extracted from aliquots (200 µL) of the serum samples using QIAzol and 79 the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's 80 protocol. The library was prepared using the QIAseq miRNA Library Kit (Qiagen). 81 Library preparations were subjected to quality control using either a Bioanalyzer 2100 or 82 TapeStation 4200 system (Agilent Technologies, Santa Clara, CA, USA). The library 83 pools were quantified using the Library Quantification Kit (Takara, Shiga, Japan) and 84 sequenced on the NovaSeq 6000 sequencing platform (Illumina Inc, San Diego, CA, USA). Reads were pre-processed and annotated against miRBase v22.1 and Ensembl 85 86 non-coding RNA database release 100 by using CLC Genomics Workbench v20.0.1. Raw 87 and normalized microarray data is available in the Gene Expression Omnibus database 88 (GSE158877).

89

90 Statistical analysis

91 Fisher's exact test for categorical variables and unpaired Student's *t*-test for continuous 92 variables were used to compare clinical data between two groups. To identify biomarker candidates among EV proteins and exRNAs, we initially used one-way analysis of 93 94 variance (ANOVA) to select candidates present at different levels in the three subject 95 groups (uninfected, COVID-19 Group 1, and Group 2) with P < 0.05. Principal 96 component analysis (PCA) was performed with the selected candidates using Partek 97 Genomics Suite 7.0 (Partek, St. Louis, MO, USA). Second, candidates with better 98 discrimination between Group 1 and 2 were selected based on linear discriminant analysis 99 with leave-one-out cross-validation, and subsequent ROC analysis was performed using 100 R version 3.6.3 (R Foundation for Statistical Computing, http:// www.R-project.org), 101 compute.es package version 0.2-2, hash package version 2.2.6.1, MASS package version 102 7.3-51.5, mutoss package version 0.1-12, and pROC package version 1.16.2. Optimal cut-

103 off values for each candidate were set based on the maximum point of the sum of 104 sensitivity and specificity (Youden index). Predictive sensitivity, specificity, and 105 accuracy were calculated with the corresponding cut-off value for each candidate. 106 Kaplan-Meier analysis with log-rank test and Cox regression analysis were performed 107 using IBM SPSS Statistics 25 (IBM Japan, Tokyo, Japan). The correlation plot was 108 generated using R version 3.6.3 and corrplot package version 0.84., and the unsupervised 109 hierarchical clustering analysis was performed using Partek Genomics Suite 7.0. The 110 limit of statistical significance for all analyses was defined as a two-sided P value of 0.05. 111

112

113 Supplementary Data

- 114 Figure S1. Clinical factors at admission for early prediction of COVID-19 severity.
- 115
- **Table S1**. Baseline characteristics of healthy donors and COVID-19 patients.
- 117 **Table S2**. WHO 2020 scoring for COVID-19 cases used in this study.
- 118 Table S3. Differences in clinical characteristics among healthy donors and COVID-19
- 119 patients.
- **Table S4**. EV proteins for discrimination between mild and severe COVID-19 patients.
- 121 Table S5. ExRNAs for discrimination between mild and severe COVID-19 patients.
- 122 Table S6. Univariate Cox regression analysis of the selected factors and biomarkers for
- 123 predicting COVID-19 severity in this patient cohort.
- 124



Figure S1. Clinical factors at admission for early prediction of COVID-19 severity. (a) Patient recruitment flowchart for this cohort. (b) Correlations of age, smoking index, CRP, and ALT between the three subject groups. *P* values for trend by *Pearson's* correlation analysis. Error bars represent mean \pm SEM. (c) The AUC (95% CI) for age, smoking index, CRP, and ALT evaluated by ROC analysis. (d) Kaplan-Meier curves for age, smoking index, CRP, and ALT by Log-rank test. Time represents the number of days from admission to time of onset for a severe COVID-19 related event. In each case, optimal cut-off values were used to define high and low groups.

	Patients	WHO score	WHO category	Age (10-year range)	Sex	Onset of severe events (day) [†]	The period of hospital stay	Outcome
	HD-1	0	uninfected	30's	М	-	-	-
	HD-2	0	uninfected	30's	М	-	-	-
	HD-3	0	uninfected	20's	F	-	-	-
	HD-4	0	uninfected	40's	М	-	-	-
Healthy	HD-5	0	uninfected	70's	М	-	-	-
donor	HD-6	0	uninfected	50's	М	-	-	-
	HD-7	0	uninfected	60's	М	-	-	-
	HD-8	0	uninfected	40's	М	-	-	-
	HD-9	0	uninfected	50's	М	-	-	-
	HD-10	0	uninfected	30's	F	-	-	-
	1	3→3	mild→mild	30's	М	-	15	discharged
	2	3→3	mild→mild	30's	М	-	14	discharged
	3	3→3	mild→mild	40's	М	-	10	discharged
	4	3→3	mild→mild	40's	М	-	13	discharged
	5	3→3	mild→mild	50's	М	-	21	discharged
	6	3→3	mild→mild	50's	М	-	26	discharged
	7	3→3	mild→mild	80's	М	-	28	discharged
	8	3→3	mild→mild	50's	F	-	25	discharged
	9	3→3	mild→mild	20's	F	-	11	discharged
	10	3→3	mild→mild	20's	F	-	23	discharged
Group 1	11	3→3	mild→mild	40's	F	-	15	discharged
COVID-19	12	3→3	mild→mild	40's	М	-	12	discharged
	13	3→3	mild→mild	70's	М	-	47	discharged
	14	3→3	mild→mild	40's	М	-	54	discharged
	15	3→3	mild→mild	40's	М	-	9	discharged
	16	3→3	mild→mild	50's	М	-	15	discharged
	17	3→3	mild→mild	30's	F	-	12	discharged
	18	3→3	mild→mild	50's	М	-	18	discharged
	19	3→3	mild→mild	40's	F	-	21	discharged
	20	3→3	mild→mild	30's	М	-	0	to medical facility
	21	3→3	mild→mild	30's	F	-	0	to medical facility
	22	3→3	mild→mild	40's	М	-	7	discharged
	23	3→7	$\text{mild} {\rightarrow} \text{severe}$	60's	М	5	93	discharged
	24	3→7	$\text{mild} {\rightarrow} \text{severe}$	80's	М	4	23	death (pulmonary embolism)
	25	3→7	$\text{mild} {\rightarrow} \text{severe}$	60's	М	3	138	still hospitalized
Croup 2	26	3→7	$\text{mild}{\rightarrow}\text{severe}$	70's	М	9	44	discharged
Group 2 COVID-19	27	3→7	$\text{mild} {\rightarrow} \text{severe}$	70's	М	7	29	discharged
	28	3→7	$mild{\rightarrow}severe$	70's	М	7	125	still hospitalized
	29	3→7	$\text{mild} \rightarrow \text{severe}$	50's	М	10	43	death (ARDS)
	30	3→6	$\text{mild} \rightarrow \text{severe}$	50's	М	5	31	discharged
	31	3→5	mild→ severe	50's	М	7	16	discharged

Table S1. Baseline characteristics of healthy donors and COVID-19 patients.

M, male; F, female; † Day after sampling point on admission.

Table S2. WHO 2020 scoring for COVID-19 cases used in this study.

Patient	Descriptor	Score
Uninfected	No clinical or virological evidence of infection	0
Ambulaton	No limitation of activities	1
Ambulatory	Limitation of activities	2
Hospitalized mild disease	No oxygen therapy	3
hospitalized-mild disease	Oxygen by nasal prongs or mask	4
	Non-invasive ventilation of high-flow oxygen	5
Hospitalized-severe disease	Intubation and mechanical ventilation	6
	Ventilation + additional organ support (pressors, RRT, ECMO)	7

RRT, renal replacement therapy; ECMO, extracorporeal membrane oxygenation.

	uninfected	Group 1 COVID-19 Group 2 COVID-19		P value		
	(n=10)	(n=22)	(n=9)	(uninfected vs. infected)	(Group 1 vs. Group 2)	
Age (year)	46.5 ± 14.8	45.3 ± 14.3	65.4 ± 9.5	0.42	0.001	
Sex						
Men	8 (80%)	15 (68.2%)	9 (100%)	1.00	0.08	
Women	2 (20%)	7 (31.8%)	0 (0%)			
BMI (kg/m²)	22.8 ± 4.4	23.0 ± 3.0 (n=20)	22.4 ± 3.2	0.95	0.63	
Smoking index	176 ± 237	60 ± 140	427 ± 670	0.94	0.02	
WBC count (10 ³ /µL)	6.7 ± 2.9	4.6 ± 1.5	5.2 ± 3.2	0.03	0.46	
CRP (mg/dL)	0.12 ± 0.12	2.50 ± 2.41	6.07 ± 5.11	0.01	0.01	
BUN (mg/dL)	13.7 ± 4.5	17.0 ± 16.6	22.6 ± 14.6	0.35	0.39	
Cr (mg/dL)	0.84 ± 0.13	1.72 ± 3.22	1.88 ± 2.4	0.33	0.90	
ALT (IU/L)	22.5 ± 8.5	21.4 ± 15.2	42.6 ± 33.2	0.51	0.02	
CK (IU/L)	NA	69.5 ± 44.1	71.8 ± 50.8	NA	0.90	
D-dimer (µg/mL)	NA	1.8 ± 2.0 (n=12)	1.1 ± 0.4	NA	0.28	
Fbg (mg/dL)	NA	389.0 ± 84.2 (n=7)	480.4 ± 172.2	NA	0.22	
Hypertension	2 (20.0%)	6 (27.3%)	3 (33.3%)	0.70	1.00	
Diabetes mellitus	0 (0%)	5 (22.7%)	3 (33.3%)	0.17	0.66	
Dyslipidemia	0 (0%)	4 (18.2%)	3 (33.3%)	0.16	0.38	
Colonary heart disease	0 (0%)	2 (9.1%)	0 (0%)	1.00	1.00	

Table S3. Differences in clinical characteristics among healthy donors and COVID-19 patients.

Continuous variables were expressed as mean \pm SD and tested by unpaired Student's *t*-test. Categorical variables were expressed as n (%) and tested by Fisher's exact test.

Table S4. EV proteins for discrimination between mild and severe COVID-19 patients.	
---	--

GeneName	Cross-validation score	Sensitivity	Specificity	Accuracy	AUC
COPB2	1.00	1.00	1.00	1.00	1.00
KRAS	0.90	1.00	0.82	0.87	0.93
PRKCB	0.90	0.89	0.95	0.94	0.93
RHOC	0.90	0.78	1.00	0.94	0.96
CD147	0.87	0.67	0.91	0.84	0.73
CAPN2	0.87	0.89	0.77	0.81	0.84
EGG	0.87	0.67	0.95	0.87	0.87
MFAP4	0.87	0.56	1.00	0.87	0.75
ADI1	0.84	0.67	0.95	0.87	0.88
AK1	0.84	0.89	0.91	0.90	0.95
MGAT1	0.84	1.00	0.77	0.84	0.91
CLDN3	0.84	0.89	0.82	0.84	0.86
CRP	0.84	0.78	0.77	0.77	0.82
UQCRC2	0.84	0.78	0.82	0.81	0.77
FGA	0.84	0.67	0.95	0.87	0.88
FGB	0.84	0.67	1.00	0.90	0.84
GPX1	0.84	0.78	0.82	0.84	0.81
GSK3B	0.84	0.44	1.00	0.84	0.73
LBP	0.84	0.78	0.86	0.84	0.82
PDGFC	0.84	0.89	0.77	0.81	0.86
RAB13	0.84	0.78	0.86	0.84	0.85
RAP1B	0.84	0.67	1.00	0.90	0.91
SLC6A4	0.84	0.89	0.82	0.84	0.90
UBA7	0.84	0.78	0.86	0.84	0.83
ORM1	0.81	0.89	0.59	0.68	0.80
	0.81	0.56	0.95	0.84	0.08
APOR	0.81	0.78	0.86	0.84	0.00
B4GALT1	0.81	0.67	0.95	0.87	0.79
BHMT	0.81	0.44	1.00	0.84	0.74
CPN1	0.81	0.89	0.68	0.74	0.84
GNAZ	0.81	1.00	0.95	0.97	0.99
ICAM2	0.81	1.00	0.59	0.71	0.83
SELL	0.81	0.67	0.91	0.84	0.74
MAN1A1	0.81	0.78	0.82	0.81	0.85
SERPINA5	0.81	0.89	0.82	0.84	0.81
NCE1B	0.81	0.89	0.66	0.67	0.90
TMEM59	0.81	0.44	0.95	0.81	0.59
YWHAB	0.77	0.67	0.95	0.87	0.85
ABAT	0.77	0.33	1.00	0.81	0.52
ADH1B	0.77	0.67	0.95	0.87	0.79
ASL	0.77	0.67	0.91	0.84	0.80
ASS1	0.77	0.78	0.86	0.84	0.79
CDH2	0.77	0.56	0.95	0.84	0.69
CAB39	0.77	0.89	0.91	0.90	0.94
CP31	0.77	0.67	1.00	0.77	0.74
COL 6A3	0.77	0.67	0.86	0.80	0.82
CUL4A	0.77	0.78	0.64	0.68	0.75
DSC1	0.77	0.44	0.95	0.81	0.58
ENTPD5	0.77	1.00	0.64	0.74	0.86
EIF4A1	0.77	0.67	0.86	0.81	0.80
FN1	0.77	0.89	0.68	0.74	0.81
PGC	0.77	0.89	0.68	0.74	0.78
CNAD	0.77	1.00	0.59	0.71	0.84
GNR12	0.77	0.78	0.39	0.00	0.75
GNA13	0.77	0.67	0.95	0.87	0.86
ITGA2B	0.77	0.67	0.91	0.84	0.86
ITGB1	0.77	1.00	0.59	0.71	0.84
ILK	0.77	0.89	0.77	0.81	0.84
F11R	0.77	1.00	0.50	0.65	0.82
LTA4H	0.77	0.56	0.91	0.81	0.67
LIMS1	0.77	0.89	0.77	0.81	0.83
	0.77	0.36	0.00	0.77	0.75
NNMT	0.77	0.78	0.00	0.84	0.04
NID1	0.77	0.89	0.55	0.65	0.76
PPIA	0.77	0.78	0.77	0.77	0.86
PLA1A	0.77	0.67	0.91	0.84	0.80
PPBP	0.77	0.67	0.77	0.74	0.69
PECAM1	0.77	1.00	0.55	0.68	0.82
GP1BB	0.77	0.67	0.86	0.81	0.81
PCSK9	0.77	1.00	0.82	0.87	0.91
	0.77	0.44	0.90	0.01	0.71
F2RI 3	0.77	0.07	0.02 0.86	0.77	0.74
LOX	0.77	0.67	0.91	0.84	0.81
SFTPB	0.77	0.67	0.77	0.74	0.78
RAB5B	0.77	0.78	0.86	0.84	0.84
RALB	0.77	0.89	0.68	0.74	0.82
REEP6	0.77	0.78	0.68	0.71	0.71
RETN	0.77	0.67	0.73	0.71	0.69
AGXT	0.77	0.22	1.00	0.77	0.48
	U.//	0.89	U.64	U./1	0.81
INBU ISC15	0.77	0.00	0.91	0.81	0.74
77X	0.77	1.00	0.55	0.68	0.82

Transcript	Cross-validation score	Sensitivity	Specificity	Accuracy	AUC
miR-122-5p	0.84	0.56	1.00	0.87	0.81
SNORD33	0.84	1.00	0.73	0.81	0.89
AL732437.2	0.84	0.89	0.68	0.74	0.80
RNU2-29P	0.81	0.44	1.00	0.84	0.70
CDKN2B-AS1	0.81	0.67	0.95	0.87	0.86
AL365184.1	0.81	0.78	0.86	0.84	0.87
AL365184.1	0.81	0.78	0.91	0.87	0.90
AL365184.1	0.81	0.67	0.91	0.84	0.87
AL365184.1	0.81	0.78	0.91	0.87	0.90
AL365184.1	0.81	1.00	0.73	0.81	0.92
let-7c-5p	0.77	0.44	0.95	0.81	0.75
miR-21-5p	0.77	0.56	0.91	0.81	0.71
miR-140-3p	0.77	0.89	0.77	0.81	0.89
C5orf66-AS2	0.77	0.78	0.91	0.87	0.89

Table S5. ExRNAs for discrimination between mild and severe COVID-19 patients.

	Cut-off	HR	(95% CI)	P value
Age high	56.5	28.1	(3.4 - 231.9)	0.0019
Smoking index high	87.5	3.1	(0.8 - 11.6)	0.092
CRP high	2.3	8.4	(1 - 67.5)	0.045
ALT high	21.5	3.8	(0.8 - 18.5)	0.095
COPB2 low	1.6 x10 ⁸	NA	-	-
KRAS low	4.8 x10 ⁷	189.8	(0.4 - 9.0 x10 ⁴)	0.095
PRKCB low	6.3 x10 ⁷	32.1	(3.9 - 261.9)	0.0012
RHOC low	1.4 x10 ⁷	23.6	(4.7 - 118)	0.00012
CD147 high	6.1 x10 ⁸	10.7	(2.5 - 45.1)	0.0013
CAPN2 high	7.2 x10 ⁵	15.5	(1.9 - 125.9)	0.010
ECM1 high	2.3 x10 ⁸	11.6	(2.8 - 48.4)	0.00079
FGG high	1.4 x10 ¹⁰	21.4	(4.2 - 110.4)	0.00025
MFAP4 high	4.6 x10 ⁸	12.7	(3.3 - 48.6)	0.00022
miR-122-5p high	1.0 x10 ⁵	10.5	(2.7 - 40.4)	0.00063
SNORD33 high	406.6	104.1	(0.4 - 2.7 x10 ⁴)	0.10
AL732437.2 high	8.8	9.9	(1.2 - 79.9)	0.031
RNU2-29P high	124.1	10.4	(2.6 - 40.8)	0.00081
CDKN2B-AS1 high	6.2	14.4	(3.4 - 61.3)	0.00031
AL365184.1 high	2.9	14.2	(1.8 - 114.4)	0.013

Table S6. Univariate Cox regrssion analysis of the selected factors and biomarkers for predicting COVID-19 severity in this patient cohort.

HR, hazard ratio; CI, confidence interval; NA, not applicable